Summary & Overview
HCPCS S0166: Injection, Olanzapine 2.5 mg
HCPCS Level II code S0166 denotes a 2.5 mg injection of olanzapine, an antipsychotic medication used in behavioral health settings. This code matters nationally because injectable formulations of psychotropic drugs are used for acute agitation, behavioral stabilization, and situations where oral administration is not feasible. Proper coding ensures accurate representation of medication administration and supports appropriate coverage and clinical documentation across settings.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of the code’s clinical context, typical sites of service, and the common billing modifiers associated with medication administration. The publication also outlines benchmarks and policy considerations relevant to injectable psychotropic agents, including payer reimbursement practices and administrative requirements where available.
This summary provides clinicians, coders, and policy professionals with a concise reference to the code’s meaning and operational implications. Data not available in the input will be noted explicitly in the detailed sections. The content emphasizes national applicability and focuses on coding accuracy, service classification, and payer coverage context rather than clinical guidance.
Billing Code Overview
HCPCS Level II code S0166 describes an injection of olanzapine, 2.5 mg. This code represents a single administration of the antipsychotic medication olanzapine at the 2.5 mg dose.
Service Type: Medication administration (injectable antipsychotic)
Typical Site of Service: Outpatient clinic, behavioral health clinic, emergency department, or other outpatient facility where injectable psychotropic medications are administered.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with schizophrenia, schizoaffective disorder, or an acute agitation episode requiring intramuscular antipsychotic therapy. The patient presents to an outpatient mental health clinic, emergency department, or an inpatient psychiatric unit with worsening psychosis, severe agitation, or poor adherence to oral antipsychotic medication. After psychiatric assessment and confirmation of indication, the clinician documents rationale for injectable therapy and obtains informed consent. A registered nurse prepares and administers S0166 (injection, olanzapine, 2.5 mg) via intramuscular route, typically into the deltoid or gluteal muscle, following facility medication administration protocols and post-injection monitoring for sedation and orthostatic changes. Vital signs and mental status are reassessed at intervals per policy. Documentation includes medication name and dose (olanzapine 2.5 mg), time, route, injection site, lot number, informed consent, pre- and post-vital signs, patient tolerance, and any adverse events. Billing uses HCPCS Level II code S0166 and may include appropriate modifiers to reflect special circumstances such as anatomic site or reduced services.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 |